Pathway Genomics and Susan G. Komen Partner in Fight against Breast Cancer

Pathway Genomics donates money and fifty BRCA1 and BRCA2 breast cancer tests at no-charge for patients at high risk

SAN DIEGO--()--Pathway Genomics and Susan G. Komen, the largest source of nonprofit funds dedicated to the fight against breast cancer, have announced a partnership to educate women about the screening options available to detect a predisposition to breast cancer. In addition to cash donations Pathway Genomics will provide genetic testing to women in need at no charge. The BRCA1 and BRCA2 genes are a component of Pathway Genomics’ comprehensive Hereditary Cancer DNA InsightSM product, currently scheduled for release in August.

Prior to the recent Supreme Court ruling that invalidated certain patent claims covering BRCA1 and BRCA2 genes, testing for risk of breast and ovarian cancers has been unaffordable for many with tests costing as much as $7000. Pathway Genomics’ test will be more accessible and affordable to patients who are at high risk for breast cancer.

More than 40,000 people in the U.S. die annually from breast cancer. “Providing patients with proper education and affordable hereditary cancer screening is extremely important to Pathway Genomics and will help pave the way to saving thousands of lives each year,” said Jim Plante, Pathway Genomics’ founder and CEO.

“We are grateful for Pathway Genomics’ generous donation of free breast cancer testing and excited to see a San Diego-based organization making this type of testing available to those who need it most regardless of their monetary situation,” said Laura Farmer Sherman, Executive Director of Susan G. Komen for the Cure, San Diego.

In addition to testing for breast cancer, Pathway Genomics’ physician authorized testing services will screen over 30 genes linked to inherited cancers including ovarian, thyroid, renal, colorectal (Lynch Syndrome), and prostate. Providing physicians and patients with powerful information about cancer risks will help them to make educated decisions about preventative measures and treatment options.

About Pathway Genomics Corporation

As a CAP-accredited and CLIA-certified clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cardiac health, cancer risk, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health.

For more about Pathway Genomics visit www.pathway.com.

About Susan G. Komen for the Cure®, San Diego

Since its inception in 1995, Komen San Diego has raised more than $11.9 million to fund local non-profits who provide everything from free diagnostic mammograms and surgeries to meal delivery, child care and temporary financial aid. Seventy-five percent of every dollar raised in San Diego stays right here in San Diego County to fund free diagnostic mammograms, treatment and services for uninsured and underinsured women and their families. With $1.4 million at work in San Diego County, Komen San Diego continues to be the County’s largest funder of free breast cancer treatments, services and support for uninsured women and their families. The remaining 25 percent funds international breast cancer research. In fact, next to the U.S. government, Susan G. Komen for the Cure® is the largest funder of breast cancer research in the world. For more information, please visit www.komensandiego.org.

Contacts

Pathway Genomics Corporation
K’Lene Oen, +1-858-229-1070
klene.oen@pathway.com

Release Summary

Pathway Genomics donates money and fifty breast cancer screening tests to Susan G. Komen. Pathways' test will be more accessible and affordable to patients who are at high risk for breast cancer.

Sharing

Contacts

Pathway Genomics Corporation
K’Lene Oen, +1-858-229-1070
klene.oen@pathway.com